Randomized controlled trial of a remote-guided caffeine reduction intervention
Knerr AW, Strickland JC, Labos BH, Lee DC
Drug and alcohol dependence · 0 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute on Drug Abuse
- Gobierno
- NIDA NIH HHS
- Subvenciones
- National Institute on Drug Abuse (R01 DA003890); National Institute on Drug Abuse (T32DA007209)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-03-12 · Drug Alcohol Depend · vol. 283 · pág. 113123
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 21% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Coffee research and impacts · Substance Abuse Treatment and Outcomes · Sleep and related disorders
- Palabras clave
- caffeine reduction, remote intervention, manualized treatment, sleep, anxiety, reflux, diarrhea, drug use, treatment accessibility
- MeSH
- humans, caffeine, central nervous system stimulants, treatment outcome, adult, female, male, young adult
4 autores
- Alexandra W. Knerr🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Justin C. Strickland🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Breanna H. Labos🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Dustin C. Lee🇺🇸 · autor de correspondenciaJohns Hopkins University; Johns Hopkins Medicine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Introduction
Caffeine is the most widely used psychoactive substance. Although one third of individuals who chronically consume caffeine express a desire to reduce caffeine consumption, empirically supported interventions for caffeine reduction are limited. This fully-remote randomized controlled trial assessed a manualized caffeine fading intervention for reducing caffeine use and adverse caffeine-related symptoms.
Methods
In this two-arm, parallel, open-label waitlist control study, healthy adults with interest in reducing their caffeine consumption and reported adverse caffeine-related symptoms were urn randomized to receive a caffeine fading treatment manual immediately or after a six-week delay. The manual guided participants in systematically reducing caffeine consumption over the six-week intervention. Caffeine-related symptoms were also measured throughout the intervention and up to 14 weeks post-treatment.
Results
Data were analyzed for all randomized participants, with 56 in the delayed treatment group and 53 in the immediate treatment group. Caffeine consumption decreased from a mean of 565mg per day (SD=295) at screening to 233mg (SD=226) post treatment (p < .0001, d=1.26). Caffeine consumption in the delayed treatment group did not significantly decrease prior to the intervention. Reductions were also seen in adverse caffeine-related symptoms, with decreases in PROMIS t-scores for sleep, anxiety, reflux, and diarrhea (d=0.67-1.04).
Conclusion
Participants successfully reduced caffeine use using the manual, showing its feasibility as a standalone intervention. This is the first clinical trial of caffeine reduction treatment done without clinical supervision. Future efforts should increase accessibility by adapting the manual to digital modalities.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.